tbuckley/cabot-search huggingface dataset:
Abstract 4144502: <i>Comparing Readmission Rates and Exercise Capacity Following Left Ventricular Assistive Device Placement With and Without Post-Operative Inpatient Rehabilitation</i>
Authors: Lauren Cuenant, Junaid Raja, Eduard Tiozzo, Nicole Pontee
Journal: Circulation (2024)

Introduction: Patients with heart failure may undergo mechanical assistive device placement as a bridge to heart transplantation or for destination therapy. Thereafter, patients may be discharged home or admitted to inpatient rehabilitation. Research Question: We hypothesized that within 8 months, patients admitted to inpatient rehabilitation (IR) would have fewer readmissions and greater exercise capacity compared to patients discharged home following left ventricular assistive device (LVAD) placement. Aim: The readmission rates and exercise capacity of patients admitted to (IR) were compared to those discharged home within 8 months of (LVAD) placement. Methods: Readmission rates, impairment percentages (IP) (determined by Activity Measure for Post-Acute Care scores) and walking distance after (LVAD) placement between March 1 st , 2020 to November 30 th , 2022 were collected via retrospective chart review at Jackson Memorial Hospital. Adults with heart failure and heart assistive device (ICD10 code Z95.811), discharged home or admitted to the Christine E. Lynn Rehabilitation Center for at least 7 consecutive days within 8 months were included. Patients who were noncompliant, expired, transferred, or unable to ambulate were excluded. 24 patients were admitted to rehab, and 16 were discharged home. Statistical significance was denoted at the 0.05 level using the Mann-Whitney U Test. Results: There was a higher proportion of females in the rehab group (45.8%) and males in the no rehab group (93.8%) (p=0.02). The groups were otherwise comparable. Average (IP) at hospital discharge was higher for the rehab group (51.79%, SD 17.65) compared to the no rehab group (14.20%, SD 18.93) (p&lt;.001). Average post-(LVAD) walking distance (feet) at hospital discharge was higher for the no rehab group (305, SD 206.72) compared to the rehab group (127.73, SD 132.11) (p=0.005). Within 8 months, there was no significant difference between groups. Average readmissions were higher for the no rehab group (1.375, SD 0.957) compared to the rehab group (0.958, SD 1.49) (p= 0.059), but was not statistically significant. Conclusions: Patients with greater (IP) and shorter walking distances were admitted to rehab and became functionally comparable to the no rehab group by 8 months. Though readmission rates were lower for the rehab group, this was not statistically significant. Additional studies are warranted to evaluate the impact of (IR) following (LVAD) placement.
Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy (Adv. Healthcare Mater. 28/2024)
Authors: Fei Kang, Meng Niu, Zijian Zhou, Mingru Zhang, Hehe Xiong, Fantian Zeng, Jing Wang, Xiaoyuan Chen
Journal: Advanced Healthcare Materials (2024)
Preventive catheter ablation for ventricular arrhythmias in patients with end‐stage heart failure referred for heart transplantation evaluation: Rationale for and design of the <scp>CASTLE</scp>‐<scp>VT</scp> trial
Authors: Christian Sohns, Thomas Fink, Harry J.G.M. Crijns, Angelika Costard‐Jaeckle, Nassir F. Marrouche, Samuel Sossalla, Rene Schramm, Mustapha El Hamriti, Maximilian Moersdorf, Maxim Didenko, Martin Braun, Vanessa Sciacca, Frank Konietschke, Volker Rudolph, Jan Gummert, Jan G.P. Tijssen, Philipp Sommer
Journal: European Journal of Heart Failure (2024)

Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx). The purpose of the Preventive Catheter Ablation for ventricular arrhythmiaS in patients with end-sTage heart faiLure rEferred for heart transplantation eValuaTion (CASTLE-VT) trial is to test the hypothesis that prophylactic catheter ablation of arrhythmogenic ventricular scar tissue will reduce mortality, need for LVAD implantation, and urgent HTx in patients with end-stage HF related to ischaemic cardiomyopathy (ICM).
Magnetically Guided Adeno‐Associated Virus Delivery for the Spatially Targeted Transduction of Retina in Eyes (Adv. Healthcare Mater. 28/2024)
Authors: Seungkuk Ahn, Oliver Siontas, Janis Koester, Jacek Krol, Sascha Fauser, Daniel J. Müller
Journal: Advanced Healthcare Materials (2024)
Electrohydrodynamic Direct‐Writing Micro/Nanofibrous Architectures: Principle, Materials, and Biomedical Applications (Adv. Healthcare Mater. 28/2024)
Authors: Zhengjiang Liu, Jinqiao Jia, Qi Lei, Yan Wei, Yinchun Hu, Xiaojie Lian, Liqin Zhao, Xin Xie, Haiqing Bai, Xiaomin He, Longlong Si, Carol Livermore, Rong Kuang, Yi Zhang, Jiucun Wang, Zhaoyan Yu, Xudong Ma, Di Huang
Journal: Advanced Healthcare Materials (2024)
Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer (Adv. Healthcare Mater. 28/2024)
Authors: Bingqi Dong, Yanlun Gu, Xiaojiao Sun, Xin Wang, Ying Zhou, Zhuona Rong, Jixin Zhang, Xuedong Shi, Zhuo Zhang, Xu He, Lin Chen, Qingqing Xiong, Xiaocong Pang, Yimin Cui
Journal: Advanced Healthcare Materials (2024)
Topical Nanoliposomal Collagen Delivery for Targeted Fibril Formation by Electrical Stimulation (Adv. Healthcare Mater. 28/2024)
Authors: Albertus Ivan Brilian, Sang Ho Lee, Agustina Setiawati, Chang Ho Kim, Soo Ryeon Ryu, Hyo‐Jin Chong, Yejin Jo, Hayan Jeong, Bong‐Gun Ju, Oh‐Sun Kwon, Giyoong Tae, Kwanwoo Shin
Journal: Advanced Healthcare Materials (2024)
Biomimetic Nano‐Regulator that Induces Cuproptosis and Lactate‐Depletion Mediated ROS Storm for Metalloimmunotherapy of Clear Cell Renal Cell Carcinoma (Adv. Healthcare Mater. 28/2024)
Authors: Xiaotong Xu, Huimin Li, Binghua Tong, Weijie Zhang, Xiaofei Wang, Yue Wang, Geng Tian, Zhaowei Xu, Guilong Zhang
Journal: Advanced Healthcare Materials (2024)
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
Authors: W J McDaid, L Wilson, H Adderley, A Martinez-Lopez, M J Baker, J Searle, L Ginn, T Budden, M Aldea, A Marinello, J V Aredo, A Viros, B Besse, H A Wakelee, F Blackhall, S Castillo-Lluva, C R Lindsay, A Malliri
Journal: Molecular Cancer (2024)

KRASG12C and KRASG12D inhibitors represent a major translational breakthrough for non-small cell lung cancer (NSCLC) and cancer in general by directly targeting its most mutated oncoprotein. However, resistance to these small molecules has highlighted the need for rational combination partners necessitating a critical understanding of signaling downstream of KRAS mutant isoforms. We contrasted tumor development between KrasG12C and KrasG12D genetically engineered mouse models (GEMMs). To corroborate findings and determine mutant subtype-specific dependencies, isogenic models of KrasG12C and KrasG12D initiation and adaptation were profiled by RNA sequencing. We also employed cell line models of established KRAS mutant NSCLC and determined therapeutic vulnerabilities through pharmacological inhibition. We analysed differences in survival outcomes for patients affected by advanced KRASG12C or KRASG12D-mutant NSCLC. KRASG12D exhibited higher potency in vivo, manifesting as more rapid lung tumor formation and reduced survival of KRASG12D GEMMs compared to KRASG12C. This increased potency, recapitulated in an isogenic initiation model, was associated with enhanced PI3K-AKT-mTOR signaling. However, KRASG12C oncogenicity and downstream pathway activation were comparable with KRASG12D at later stages of tumorigenesis in vitro and in vivo, consistent with similar clinical outcomes in patients. Despite this, established KRASG12D NSCLC models depended more on the PI3K-AKT-mTOR pathway, while KRASG12C models on the MAPK pathway. Specifically, KRASG12D inhibition was enhanced by AKT inhibition in vitro and in vivo. Our data highlight a unique combination treatment vulnerability and suggest that patient selection strategies for combination approaches using direct KRAS inhibitors should be i) contextualised to individual RAS mutants, and ii) tailored to their downstream signaling.
False-Positive Radioiodine Uptake Related to Posttraumatic Scab Demonstrated by SPECT/CT in a Patient With Differentiated Thyroid Cancer
Authors: Romane Mostowski, Michel de Pontville, Stéphane Bardet, Renaud Ciappuccini
Journal: Clinical Nuclear Medicine (2024)

A 20-year-old man with papillary thyroid cancer received a fourth radioiodine regimen to treat 131I-avid lung metastases. Posttherapeutic whole-body scan revealed focal radioiodine uptake on the anterior region of the left lower limb that was not visible on previous whole-body scan and which suggested skin contamination. Visual examination of the left leg evidenced a posttraumatic scab caused by a fall 2 weeks before. Skin metastasis was ruled out. 131I SPECT/CT acquisition ruled out bony uptake and confirmed that the skin uptake was related to the superficial scab.
First-in-Human
Authors: Mathias Loft, Andreas Clemmensen, Emil Nørgaard Christensen, Charlotte Lund Denholt, Helle Hjorth Johannesen, Nic Gillings, Esben Andreas Carlsen, Malene Martini Clausen, Martin Hutchings, Thomas Lund Andersen, Jan Henrik Ardenkjær-Larsen, Andreas Kjaer
Journal: Clinical Nuclear Medicine (2024)

Hyperpolarized 1-13C-pyruvate magnetic resonance spectroscopy (MRS) and MRS imaging (MRSI) offer noninvasive and real-time direct assessment of the altered metabolism of cancer cells known as the Warburg effect-a key hallmark of cancer. When combined with simultaneously acquired 18F-FDG PET in a PET/MR scanner, coined hyperPET by us, this dual-modality may unveil cancer-type specific glucose metabolic phenotypes with potential implications for patient prognostication, treatment-response assessment, and prediction. We here present the first human data of simultaneously acquired hyperpolarized MRS/MRSI and PET performed in a PET/MR scanner-and the first human hyperpolarized MRS/MRSI data from a patient with lymphoma.
18F-FDG and 68Ga-Pentixafor PET/CT Findings in Patient With Multicenter Castleman Disease
Authors: Xi Chen, Feiyu Zhang, Ziyang Yuan, Ya Liu, Zhanwen Huang
Journal: Clinical Nuclear Medicine (2024)

Castleman disease is a rare lymphoproliferative disorder primarily affecting lymph nodes, including unicentric and multicentric types. The multicentric form is rarer and can often be misdiagnosed as lymphoma. Here, we report 18F-FDG and 68Ga-pentixafor PET/CT findings in a case of Castleman disease involving the nasopharynx and multiple lymph nodes.
2024 American Heart Association and American Academy of Pediatrics Focused Update on Special Circumstances: Resuscitation Following Drowning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
Authors: Cameron Dezfulian, Tracy E. McCallin, Joost Bierens, Cody L. Dunne, Ahamed H. Idris, Andrew Kiragu, Melissa Mahgoub, Rohit P. Shenoi, David Szpilman, Mark Terry, Janice A. Tijssen, Joshua M. Tobin, Alexis A. Topjian
Journal: Circulation (2024)

Drowning is the third leading cause of death from unintentional injury worldwide, accounting for 7% of all injury-related deaths. The World Health Organization estimates that there are ≈236 000 deaths due to drowning worldwide each year. Significant efforts have focused on creating systems to prevent drowning, but an average of 4000 fatal and 8000 nonfatal drownings still occur annually in the United States-likely an underestimate. Drowning generally progresses from initial respiratory arrest due to submersion-related hypoxia to cardiac arrest; thus, it can be challenging to distinguish respiratory arrest from cardiac arrest because pulses are difficult to accurately palpate within the recommended 10-second window. Therefore, resuscitation from cardiac arrest attributable to this specific circumstance must focus on restoring breathing as much as it does circulation. Resuscitation from drowning may begin with in-water rescue breathing when safely provided by rescuers trained in the technique and should continue with chest compressions, in keeping with basic life support guidelines, once the drowned individual and the rescuer are in a safe environment (eg, dry land, a boat). This focused update incorporates systematic reviews from 2021 to 2023 performed by the International Liaison Committee on Resuscitation related to the resuscitation of drowning. These clinical guidelines are the product of a committee of experts representing the American Heart Association and the American Academy of Pediatrics. The writing group reviewed the recent International Liaison Committee on Resuscitation systematic reviews, including updated literature searches, prior guidelines related to resuscitation from cardiac arrest following drowning, and other drowning-related publications from the American Heart Association and American Academy of Pediatrics. The writing group used these reviews to update its recommendations aimed at resuscitation of cardiac arrest following drowning in adults and children.
Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections
Authors: Patrick Benoit, Noah Brazer, Mikael de Lorenzi-Tognon, Emily Kelly, Venice Servellita, Miriam Oseguera, Jenny Nguyen, Jack Tang, Charles Omura, Jessica Streithorst, Melissa Hillberg, Danielle Ingebrigtsen, Kelsey Zorn, Michael R Wilson, Tim Blicharz, Amy P Wong, Brian O'Donovan, Brad Murray, Steve Miller, Charles Y Chiu
Journal: Nature Medicine (2024)

Metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) is an agnostic method for broad-based diagnosis of central nervous system (CNS) infections. Here we analyzed the 7-year performance of clinical CSF mNGS testing of 4,828 samples from June 2016 to April 2023 performed by the University of California, San Francisco (UCSF) clinical microbiology laboratory. Overall, mNGS testing detected 797 organisms from 697 (14.4%) of 4,828 samples, consisting of 363 (45.5%) DNA viruses, 211 (26.4%) RNA viruses, 132 (16.6%) bacteria, 68 (8.5%) fungi and 23 (2.9%) parasites. We also extracted clinical and laboratory metadata from a subset of the samples (n = 1,164) from 1,053 UCSF patients. Among the 220 infectious diagnoses in this subset, 48 (21.8%) were identified by mNGS alone. The sensitivity, specificity and accuracy of mNGS testing for CNS infections were 63.1%, 99.6% and 92.9%, respectively. mNGS testing exhibited higher sensitivity (63.1%) than indirect serologic testing (28.8%) and direct detection testing from both CSF (45.9%) and non-CSF (15.0%) samples (P < 0.001 for all three comparisons). When only considering diagnoses made by CSF direct detection testing, the sensitivity of mNGS testing increased to 86%. These results justify the routine use of diagnostic mNGS testing for hospitalized patients with suspected CNS infection.
Evolution of sex-linked genes and the role of pericentromeric regions in sex chromosomes: insights from diploid willows
Authors: Yi Wang, Ren-Gang Zhang, Elvira Hörandl, Zhi-Xiang Zhang, Deborah Charlesworth, Li He
Journal: Molecular Biology and Evolution (2024)

Abstract The evolution of sex chromosomes can involve recombination suppression sometimes involving structural changes, such as inversions, allowing subsequent rearrangements, including inversions and gene transpositions. In the two major genus Salix clades, Salix and Vetrix, almost all species are dioecious, and sex-linked regions have evolved on chromosome 7 and 15, with either male or female heterogamety. We used chromosome conformation capture (Hi-C) and PacBio HiFi (high-fidelity) reads to assemble chromosome-level, gap-free X and Y chromosomes from both clades, S. triandra (15XY system), a basal species in the Vetrix clade, and the Salix clade species S. mesnyi (7XY system). Combining these with other available genome assemblies, we found inversions within the sex-linked regions, which are likely to be pericentromeric and probably recombined rarely in the ancestral species, before sex-linkage evolved. The Y-linked regions in all 15XY and 7XY species include partial duplicates containing exon 1 of an ARR17-like gene similar to male-determining factors in other Salicaceae species. We also found duplicates of a Y-specific gene, which we named MSF. The derived Salix clade 7XY chromosome systems appear to have evolved when these two genes transposed from the 15Y to the 7Y. Additionally, the 7Y chromosomes in S. dunnii and S. chaenomeloides probably evolved from the ancestral 7X of the Salix clade, involving a similar transposition, and loss of the ancestral 7Y. We suggest that pericentromeric regions that recombine infrequently may facilitate the evolution of sex linkage.
Disease-associated B cells and immune endotypes shape adaptive immune responses to SARS-CoV-2 mRNA vaccination in human SLE
Authors: Caterina E Faliti, Trinh T P Van, Fabliha A Anam, Narayanaiah Cheedarla, M Elliott Williams, Ashish Kumar Mishra, Sabeena Y Usman, Matthew C Woodruff, Geoff Kraker, Martin C Runnstrom, Shuya Kyu, Daniel Sanz, Hasan Ahmed, Midushi Ghimire, Andrea Morrison-Porter, Hannah Quehl, Natalie S Haddad, Weirong Chen, Suneethamma Cheedarla, Andrew S Neish, John D Roback, Rustom Antia, Jennifer Hom, Christopher M Tipton, John M Lindner, Eliver Ghosn, Surender Khurana, Christopher D Scharer, Arezou Khosroshahi, F Eun-Hyung Lee, Ignacio Sanz
Journal: Nature Immunology (2024)

Severe acute respiratory syndrome coronavirus 2 mRNA vaccination has reduced effectiveness in certain immunocompromised individuals. However, the cellular mechanisms underlying these defects, as well as the contribution of disease-induced cellular abnormalities, remain largely unexplored. In this study, we conducted a comprehensive serological and cellular analysis of patients with autoimmune systemic lupus erythematosus (SLE) who received the Wuhan-Hu-1 monovalent mRNA coronavirus disease 2019 vaccine. Our findings revealed that patients with SLE exhibited reduced avidity of anti-receptor-binding domain antibodies, leading to decreased neutralization potency and breadth. We also observed a sustained anti-spike response in IgD
Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability
Authors: Joseph Therriault, Shorena Janelidze, Andréa Lessa Benedet, Nicholas J Ashton, Javier Arranz Martínez, Armand Gonzalez-Escalante, Bruna Bellaver, Daniel Alcolea, Agathe Vrillon, Helmet Karim, Michelle M Mielke, Chang Hyung Hong, Hyun Woong Roh, José Contador, Albert Puig Pijoan, Alicia Algeciras-Schimnich, Prashanthi Vemuri, Jonathan Graff-Radford, Val J Lowe, Thomas K Karikari, Erin Jonaitis, Wagner Brum, Cécile Tissot, Stijn Servaes, Nesrine Rahmouni, Arthur C Macedo, Jenna Stevenson, Jaime Fernandez-Arias, Yi-Ting Wang, Marcel S Woo, Manuel A Friese, Wan Lu Jia, Julien Dumurgier, Claire Hourregue, Emmanuel Cognat, Pamela Lukasewicz Ferreira, Paolo Vitali, Sterling Johnson, Tharick A Pascoal, Serge Gauthier, Alberto Lleó, Claire Paquet, Ronald C Petersen, David Salmon, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Erik Stomrud, Douglas Galasko, Sang Joon Son, Henrik Zetterberg, Juan Fortea, Marc Suárez-Calvet, Clifford R Jack, Kaj Blennow, Oskar Hansson, Pedro Rosa-Neto
Journal: Nature Aging (2024)

Abstract Recently approved anti-amyloid immunotherapies for Alzheimer’s disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce the need for PET or CSF testing; however, their interpretation at the individual level and the circumstances requiring confirmatory testing are poorly understood. Individual-level interpretation of diagnostic test results requires knowledge of disease prevalence in relation to clinical presentation (clinical pretest probability). Here, in a study of 6,896 individuals evaluated from 11 cohort studies from six countries, we determined the positive and negative predictive value of five plasma biomarkers for amyloid-β pathology in cognitively impaired individuals in relation to clinical pretest probability. We observed that p-tau217 could rule in amyloid-β pathology in individuals with probable AD dementia (positive predictive value above 95%). In mild cognitive impairment, p-tau217 interpretation depended on patient age. Negative p-tau217 results could rule out amyloid-β pathology in individuals with non-AD dementia syndromes (negative predictive value between 90% and 99%). Our findings provide a framework for the individual-level interpretation of plasma biomarkers, suggesting that p-tau217 combined with clinical phenotyping can identify patients where amyloid-β pathology can be ruled in or out without the need for PET or CSF confirmatory testing.
The prognostic impact of <i>CDKN2A/B</i> hemizygous deletions in IDH-mutant glioma
Authors: Franziska M Ippen, Thomas Hielscher, Dennis Friedel, Kirsten Göbel, David Reuss, Christel Herold-Mende, Sandro Krieg, Andreas v Deimling, Wolfgang Wick, Felix Sahm, Abigail K Suwala
Journal: Neuro-Oncology (2024)

Abstract Background Homozygous deletions of CDKN2A/B are known to predict poor prognosis in gliomas, but the impact of hemizygous deletions is less clear. This study aimed to evaluate the prognostic significance of hemizygous CDKN2A/B deletions in IDH-mutant low-grade astrocytomas and oligodendrogliomas. Methods Tissue samples diagnosed as astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant, 1p/19q co-deleted CNS WHO grade 2 and 3 were collected from the archives of the Institute of Neuropathology in Heidelberg. DNA methylation analysis was performed on formalin-fixed paraffin-embedded samples. Evaluation of the CDKN2A/B locus was performed by visual inspection of copy-number plots derived from methylation-array data for each case. Hemizygous and homozygous losses were assessed in relation to whole chromosomal or larger segmental losses and gains in the chromosomal profile. Survival probabilities were assessed using the Kaplan–Meier method. Results A total of 334 low-grade glioma cases were identified, including 173 astrocytomas and 161 oligodendrogliomas. Hemizygous deletions in CDKN2A/B (37/173 in astrocytomas, 15/161 in oligodendrogliomas) did not confer significantly worse survival outcomes compared to CDKN2A/B wild-type cases in neither low-grade astrocytoma (log-rank P = .2556; HR 2.29, 95% CI [0.76; 6.40], P = .135) nor oligodendroglioma (log-rank P = .2760; HR 0.17; 95% CI [0.01; 5.05]; P = .305), regardless of CNS WHO grade, which was further demonstrated on a subgroup of astrocytoma, IDH mutant CNS WHO 4 cases (log-rank P = .1680; HR 4.55, 95% CI [0.88; 24.51], P = .0689). Conclusions Hemizygous CDKN2A/B deletions do not significantly worsen OS or progression-free survival in IDH-mutant astrocytomas and oligodendrogliomas, CNS WHO grades 2 and 3.